Stifel Financial Corp Has $1.66 Million Position in Hologic, Inc. (NASDAQ:HOLX)

Stifel Financial Corp raised its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 115.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 20,354 shares of the medical equipment provider's stock after purchasing an additional 10,924 shares during the period. Stifel Financial Corp's holdings in Hologic were worth $1,658,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of HOLX. Innealta Capital LLC acquired a new position in shares of Hologic in the 2nd quarter valued at approximately $25,000. Wolff Wiese Magana LLC bought a new position in Hologic in the third quarter valued at approximately $25,000. Sunbelt Securities Inc. acquired a new position in shares of Hologic in the second quarter valued at approximately $37,000. First Horizon Advisors Inc. increased its position in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after acquiring an additional 134 shares in the last quarter. Finally, Cromwell Holdings LLC raised its holdings in shares of Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider's stock worth $44,000 after acquiring an additional 416 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on HOLX. Wolfe Research assumed coverage on shares of Hologic in a research note on Friday, December 13th. They issued a "peer perform" rating for the company. Raymond James upped their price objective on Hologic from $93.00 to $95.00 and gave the stock an "outperform" rating in a research report on Tuesday, November 5th. StockNews.com upgraded Hologic from a "hold" rating to a "buy" rating in a report on Thursday, November 14th. Leerink Partners cut their target price on Hologic from $95.00 to $90.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 8th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $90.00 price target on shares of Hologic in a research note on Thursday. Six equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $89.50.

Hologic Stock Performance

NASDAQ HOLX traded up $0.89 on Friday, hitting $71.65. 8,560,791 shares of the stock were exchanged, compared to its average volume of 1,672,050. The company has a market capitalization of $16.26 billion, a PE ratio of 21.52, a P/E/G ratio of 2.38 and a beta of 0.96. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The business's fifty day moving average is $78.49 and its 200 day moving average is $78.50. Hologic, Inc. has a 52 week low of $70.36 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company had revenue of $987.90 million for the quarter, compared to analysts' expectations of $978.25 million. During the same period in the prior year, the firm earned $0.89 EPS. Hologic's quarterly revenue was up 4.5% compared to the same quarter last year. Research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Activity

In related news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company's stock, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.75% of the company's stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.